1. Advances in Peanut Allergy Immunotherapy: When Science Meets Technology

2. Program Agenda

3. Welcome and Introductions

4. Peanut Allergy Prevalence and Natural Course

5. The Burden of Accidental Exposures

6. Immunotherapy Strategies Aim to Balance Efficacy, Safety, and Practicality

7. The Care Team

8. Pathophysiology of Peanut Allergy

9. The Skin as an Immune Organ Early Peanut Allergen Exposure

10. LEAP-On Prevalence of Peanut Allergy 12 Months After Avoidance

11. Recommendations for Risk Reduction of Peanut Allergy in Infants

12. Goals for Minimized Risk to Unintentional Peanut Exposure

13. Modeling of Risk Assessment

14. What Is the Clinical Relevance of a Higher Threshold?

15. Allergen Immunotherapy: Review of Phase 3 Data

16. Peanut Allergen Immunotherapy*

17. PALISADE Phase 3 Trial

18. PALISADE Safety Data

19. ARC003 Discontinuations in AR101 Group

20. Phase 3 PEPITES Study (Children 4 to 11 Years of Age) Results

21. Phase 3 PEPITES Study (Children 4 to 11 Years of Age) Preliminary Results

22. REAL Life Use and Safety of EPIT (REALISE) Study Design and Preliminary Results[a,b]

23. Advantages and Disadvantages of Peanut Allergy Immunotherapy

24. From Bench to Bedside: Case-Based Discussion

25. Case 1 Noah

26. Considerations for Managing Peanut Allergy in a Young Child

27. Case 2 Ben

28. Managing Peanut Allergy in a Preschooler

29. Case 3 Sabrina

30. Developing a Long-Term Management Strategy

31. Conclusions

32. Abbreviations